StockCIK 2023658
Bicara Therapeutics Inc. (BCAX): Insider Trades and Fund Holdings
In the past 12 months, Bicara Therapeutics Inc. insiders reported 0 open-market purchases worth $0 and 1 sale worth $401K; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$401KSold by insiders, 12 months
0Tracked funds holding
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Oct 21, 2026Planned saleDAVID RABEN (officer) filed notice to sell about $449,026 around Oct 21, 2026
- Sep 8, 2026Insider saleCEO Ryan Cohlhepp sold $400,716 under a 10b5-1 plan
- Sep 8, 2026Planned saleCohlhepp Ryan (officer, director) filed notice to sell about $396,200 around Sep 8, 2026
- Sep 8, 2026Planned saleHyep Ivan (officer) filed notice to sell about $283,000 around Sep 8, 2026
- Aug 25, 2026NewsCompany reported: Signed a material agreement
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 10, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 10 | Ryan CohlheppCEO | ▼ SELL10b5-1 | $401K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Ryan Cohlhepp | CEO | 0 | $0 | 1 | $401K |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →